

UNIVERSITY OF BIRMINGHAM

Research at Birmingham

In contrast to other species, -Galactosylceramide (-GalCer) is not an immunostimulatory NKT cell agonist in horses

Dossa, Robson G.; Alperin, Debra C.; Garzon, Diana; Mealey, Robert H.; Brown, Wendy C.; Jervis, Peter; Besra, Gurdyal; Cox, Liam; Hines, Stephen A.

DOI:

[10.1016/j.dci.2014.11.005](https://doi.org/10.1016/j.dci.2014.11.005)

License:

Other (please specify with Rights Statement)

Document Version

Peer reviewed version

Citation for published version (Harvard):

Dossa, RG, Alperin, DC, Garzon, D, Mealey, RH, Brown, WC, Jervis, PJ, Besra, GS, Cox, LR & Hines, SA 2015, 'In contrast to other species, -Galactosylceramide (-GalCer) is not an immunostimulatory NKT cell agonist in horses', *Developmental & comparative immunology*, vol. 49, no. 1, pp. 49-58. <https://doi.org/10.1016/j.dci.2014.11.005>

[Link to publication on Research at Birmingham portal](#)

Publisher Rights Statement:

NOTICE: this is the author's version of a work that was accepted for publication in *Developmental & Comparative Immunology*. Changes resulting from the publishing process, such as peer review, editing, corrections, structural formatting, and other quality control mechanisms may not be reflected in this document. Changes may have been made to this work since it was submitted for publication. A definitive version was subsequently published in *Developmental & Comparative Immunology*, Vol 49, Issue 1, March 2015, DOI : 10.1016/j.dci.2014.11.005.

Eligibility for repository checked March 2015.

General rights

Unless a licence is specified above, all rights (including copyright and moral rights) in this document are retained by the authors and/or the copyright holders. The express permission of the copyright holder must be obtained for any use of this material other than for purposes permitted by law.

- Users may freely distribute the URL that is used to identify this publication.
- Users may download and/or print one copy of the publication from the University of Birmingham research portal for the purpose of private study or non-commercial research.
- User may use extracts from the document in line with the concept of 'fair dealing' under the Copyright, Designs and Patents Act 1988 (?)
- Users may not further distribute the material nor use it for the purposes of commercial gain.

Where a licence is displayed above, please note the terms and conditions of the licence govern your use of this document.

When citing, please reference the published version.

Take down policy

While the University of Birmingham exercises care and attention in making items available there are rare occasions when an item has been uploaded in error or has been deemed to be commercially or otherwise sensitive.

If you believe that this is the case for this document, please contact UBIRA@lists.bham.ac.uk providing details and we will remove access to the work immediately and investigate.

Accepted Manuscript

Title: In contrast to other species, α -Galactosylceramide (α -GalCer) is not an immunostimulatory NKT cell agonist in horses

Author: Robson G. Dossa, Debra C. Alperin, Diana Garzon, Robert H. Mealey, Wendy C. Brown, Peter J. Jarvis, Gurdyal S. Besra, Liam R. Cox, Stephen A. Hines



PII: S0145-305X(14)00269-9
DOI: <http://dx.doi.org/doi: 10.1016/j.dci.2014.11.005>
Reference: DCI 2297

To appear in: *Developmental and Comparative Immunology*

Received date: 20-6-2014
Revised date: 6-11-2014
Accepted date: 6-11-2014

Please cite this article as: Robson G. Dossa, Debra C. Alperin, Diana Garzon, Robert H. Mealey, Wendy C. Brown, Peter J. Jarvis, Gurdyal S. Besra, Liam R. Cox, Stephen A. Hines, In contrast to other species, α -Galactosylceramide (α -GalCer) is not an immunostimulatory NKT cell agonist in horses, *Developmental and Comparative Immunology* (2014), <http://dx.doi.org/doi: 10.1016/j.dci.2014.11.005>.

This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

1 **In contrast to other species, α -Galactosylceramide (α -GalCer) is not an**
2 **immunostimulatory NKT cell agonist in horses**

3

4 Robson G. Dossa^a

5 Debra C. Alperin^a

6 Diana Garzon^b

7 Robert H. Mealey^a

8 Wendy C. Brown^a

9 Peter J. Jervis^c

10 Gurdyal S. Besra^c

11 Liam R. Cox^d

12 Stephen A. Hines^{a,*}

13

14 (a) Department of Veterinary Microbiology and Pathology, Washington State University,
15 College of Veterinary Medicine, P.O. Box 647040, Pullman, WA 99164-7040, USA

16 (b) Unilever Centre for Molecular Science Informatics, Department of Chemistry,
17 University of Cambridge, Lensfield Road, Cambridge CB2 1EW, UK

18 (c) School of Biosciences, University of Birmingham, Edgbaston, Birmingham B15 2TT,
19 UK

20 (d) School of Chemistry, University of Birmingham, Edgbaston, Birmingham B15 2TT,
21 UK

22

23

24 * Corresponding author: Stephen A. Hines

25

26 Mailing address: Department of Veterinary Microbiology and Pathology, Washington

27 State University, PO Box 647040, Pullman, Washington 99164-7040

28 Tel.: +1 (509) 335-6030. Fax: +1 (509) 335-8529.

29 E-mail address: shines@vetmed.wsu.edu (S. A., Hines).

30

1

2 **Highlights**

- 3 • The equine CD1d has a suitable pocket for α -GalCer ligation.
- 4 • α -GalCer failed to stimulate equine NKT cells in vitro or in vivo.
- 5 • α -GalCer loaded tetramers did not bind equine cells.
- 6 • α -GalCer is an unsuitable adjuvant in horses.
- 7 • Requirements for equine NKT cells activation is likely unique

8

9

10

11 **Abstract**

12 α -GalCer is a potent immunomodulatory molecule that is presented to NKT cells
13 via the CD1 antigen-presenting system. We hypothesized that when used as an
14 adjuvant α -GalCer would induce protective immune responses against *Rhodococcus*
15 *equi*, an important pathogen of young horses. Here we demonstrate that the equine
16 CD1d molecule shares most features found in CD1d from other species and has a
17 suitable lipid binding groove for presenting glycolipids to NKT cells. However, equine
18 CTL stimulated with α -GalCer failed to kill cells infected with *R. equi* and α -GalCer did
19 not increase killing by CTL co-stimulated with *R. equi* antigen. Likewise, α -GalCer did
20 not induce the lymphoproliferation of equine PBMC or increase the proliferation of *R.*
21 *equi*-stimulated cells. Intradermal injection of α -GalCer in horses did not increase the
22 recruitment of lymphocytes or cytokine production. Furthermore, α -GalCer-loaded
23 CD1d tetramers, which have been shown to be broadly cross-reactive, did not bind
24 equine lymphocytes. Altogether, our results demonstrate that in contrast to previously
25 described species, horses are unable to respond to α -GalCer. This raises questions

1 about the capabilities and function of NKT cells and other lipid-specific T lymphocytes in
2 horses.

3 **Keywords**

4 NKT

5 α -Galactosylceramide

6 CD1d

7 Horse

8 *Rhodococcus equi*

9

10

Accepted Manuscript

1 **1. Introduction**

2 Natural killer T (NKT) cells, are a subset of novel T lymphocytes that have
3 characteristics of classic activated or memory T cells, and express the NK 1.1 marker
4 (Makino et al., 1995). These cells share features of both the innate and adaptive
5 immune systems (Brennan et al., 2013). NKT cells are found in the circulation and
6 tissues in a primed stage (memory phenotype) that does not require prior contact with
7 foreign antigen (de Lalla et al., 2008). Upon activation, NKT cells rapidly release
8 significant amounts of both T helper type 1 (Th1) and Th2 cytokines. Although NKT cells
9 are mostly CD4⁺ or CD4⁻CD8⁻ (double negative) and can serve as helper cells, they can
10 also exert potent cytotoxic effects (Gapin et al., 2001; Kawano et al., 1998; Metelitsa et
11 al., 2001).

12 In contrast to classical T lymphocytes, which recognize antigens presented via
13 MHC molecules, NKT cells are CD1d-restricted (Bendelac et al., 1995). CD1d is a
14 member of the CD1 family, a group of non-polymorphic MHC class I-like surface
15 glycoproteins that contain a hydrophobic binding groove and are specialized in their
16 ability to present lipid-based antigens to T cells (Moody et al., 2005). The CD1d gene is
17 broadly conserved across species, and is found in all mammals studied so far with the
18 exception of marsupials (Baker and Miller, 2007).

19 A wide variety of natural exogenous ligands have been shown to bind CD1d and
20 then activate NKT cells (Fischer et al., 2004; Kinjo et al., 2011; Kinjo et al., 2006; Kinjo
21 et al., 2005). However, most studies with NKT cells are performed with a synthetic
22 analogue of a glycolipid originally derived from the marine sponge *Agelas mauritanus*,
23 α -galactosylceramide (α -GalCer). This molecule contains a saturated C26 fatty acyl
24 chain and a C18 phytosphingosine base (Kawano et al., 1997). In numerous species,

1 including humans (Spada et al., 1998), pigs (Thierry et al., 2012), rats (Monzon-
2 Casanova et al., 2010), and mice (Kawano et al., 1997), α -GalCer binds CD1d
3 molecules and is presented to specialized invariant NKT cells (iNKT cells, also called
4 Type 1 NKT cells) that recognize the glycolipid via a highly conserved T cell receptor
5 (TCR) α -chain (Borg et al., 2007). As a result, α -GalCer acts as a strong NKT cell
6 agonist. In mice, a single injection of α -GalCer can activate the NKT cell population,
7 stimulating the immediate release of cytokines including IFN- γ , IL-4, TNF, IL-2, and IL-
8 10 (Fujii et al., 2003; Nishimura et al., 2000; Reilly et al., 2012). These cytokines
9 simultaneously activate other cells including classic T cells, NK cells, monocytes, and B
10 cells. This leads to the production of more cytokines and chemokines, giving α -
11 GalCer/NKT cells a potent immunomodulatory capacity (Subrahmanyam and Webb,
12 2012).

13 The capacity of NKT cells to regulate the immune response has been shown to
14 improve the outcome of numerous vaccines (Chackerian et al., 2002; Gonzalez-
15 Aseguinolaza et al., 2002; Huang et al., 2008; Sada-Ovalle et al., 2010). In these
16 experiments, α -GalCer acts as an effective vaccine adjuvant by modulating cytokine
17 levels, boosting cytotoxic T lymphocyte (CTL) and humoral responses, as well as
18 enhancing antigen presentation by dendritic cells. A recent study in mice showed that
19 immunization with *Mycobacterium bovis* bacillus Calmette-Guerin (BCG) with α -GalCer
20 incorporated into its membrane increased protection against challenge with virulent *M.*
21 *tuberculosis* when compared to immunization with unmodified BCG (no α -GalCer)
22 (Venkataswamy et al., 2009).

1 The presence of NKT cells in horses and their ability to recognize α -GalCer
2 remains unknown. However, recent work in our laboratory identified an equine CD1
3 cluster that is composed of 13 genes (Dossa et al., 2014). This cluster includes a CD1d
4 homologue that is expressed in several antigen-presenting cells (APC), including
5 macrophages and dendritic cells. Additionally, previous work in another lab indicated
6 that horses possess a TCR α -chain that is homologous to the highly conserved TCR
7 used by human and murine iNKT cells (Looringh van Beeck et al., 2009). This equine
8 TCR was predicted to interact with equine CD1d. Together these findings strongly
9 suggest that the CD1d/NKT cell system is present in horses.

10 Little is also known about the specific roles played by CD1, the lipid antigen
11 presentation system, or NKT cells in horses. Evidence suggests that immune responses
12 to microbial lipids are essential in the protection against *Rhodococcus equi*, an
13 important equine pathogen (Vázquez-Boland et al., 2013). *R. equi* is a nocardioform
14 actinomycete bacterium that is closely related and structurally similar to *M. tuberculosis*
15 (Rahman et al., 2003). Whereas *M. tuberculosis* causes tuberculosis in humans, *R. equi*
16 causes pyogranulomatous pneumonia in horses between 2-5 months of age.
17 Rhodococcal pneumonia is a common cause of morbidity and mortality in young horses
18 worldwide. As a result of exposure early in life, adult horses are almost invariably
19 immune. Furthermore, immune adult horses have CTL that lyse *R. equi* infected cells in
20 an MHC class-I unrestricted fashion (Patton et al., 2004; Patton et al., 2005). These
21 CTL recognize unique *R. equi* lipids, presumably presented by the CD1 system (Harris
22 et al., 2010).

1 Despite the observation that naturally developing adaptive immune responses
2 strongly protect adult horses, efforts to develop a vaccine to prevent rhodococcal
3 pneumonia in foals have been unsuccessful (Lopez et al., 2003; Lopez et al., 2008;
4 Mealey et al., 2007). The need to stimulate protective cell-mediated responses in the
5 first weeks of life is likely a critical barrier. Considering that horses express a CD1d
6 molecule and carry at least one apparent NKT cell TCR homologue, we hypothesized
7 that the glycolipid α -GalCer would stimulate equine NKT cells and consequently
8 enhance the immunogenicity of an *R. equi* vaccine. In this study, we demonstrate that
9 molecular models predict that the equine CD1d (eqCD1) binding groove site will
10 accommodate and bind α -GalCer. However, we were unable to demonstrate an
11 immunomodulatory effect *in vitro* or *in vivo*, suggesting important differences between
12 horses and previously studied mammals.

1 **2. Material and methods**

2 **2.1 Construction of an eqCD1d Binding Domain Homology Model**

3 To determine the evolutionary relationship between equine CD1d (eqCD1d) and
4 CD1d from other species, an alignment of the CD1d binding domain was performed
5 using ClustalW. Subsequently, a phylogenetic analysis based on a neighbor joining tree
6 was created using MEGA v5.2 software (<http://www.megasoftware.net>) (Supplementary
7 Fig. 1).

8 A high quality model of the binding domain of the eqCD1d molecule was
9 generated using a previously described multiple template homology model protocol and
10 X-ray crystal structure data available for different species of CD1d bound to α -GalCer
11 (Garzón et al., 2009) (Supplementary Fig. 2A, B). The detailed methodology used is
12 provided in Supplementary Material and Methods.

14 **2.2 Horses**

15 Adult horses of various breeds were used in accordance with the Washington
16 State University institutional animal care and use committee. Venous blood was
17 collected from the jugular vein of each horse using evacuated containers (Baxter,
18 Deerfield, IL) containing 16% anticoagulant citrate dextrose A (ACD; Baxter). Peripheral
19 blood mononuclear cells (PBMC) were isolated from venous blood using a Ficoll-
20 Hypaque technique (Zhang et al., 1998).

22 **2.3 Bacteria**

1 The plasmid-bearing virulent *R. equi* strain ATCC 33701 bacteria were grown in
2 brain heart infusion broth (BHI; Becton Dickinson, Franklin Lakes, NJ), overnight at
3 37°C with shaking for 8h. After the 8h growth, the number of bacteria per ml was
4 estimated with an optical density reading of 0.050 Å at 600 nm (Beckman DU-64)
5 equaling 1.5×10^8 *R. equi* per ml. The bacterial concentration was confirmed by plating
6 serial dilutions on BHI plates and calculating the colony-forming units per ml.

7 **2.4 Lipids**

8 The synthetic glycolipids α -GalCer (KRN7000) and 7DW8-5 were purchased
9 from Avanti Polar Lipids, Alabaster, AL and Diagoncine, Hackensack, NJ. The
10 remaining synthetic lipids were synthesized by one of the investigators (PJJ) at the
11 School of Biosciences, University of Birmingham (Birmingham, UK), using modified
12 procedures to those described previously (Jervis et al., 2011; Jervis et al., 2010).

13 *R. equi* lipids were isolated using a previously described chloroform/methanol
14 extraction method (Harris et al. 2010). After overnight separation in a separatory funnel,
15 the organic layer was collected and dried on a rotary evaporator at 37°C. The sample
16 was then resuspended in PBS, with sonication to a concentration of 10 μ g/ml.

17 **2.5 Cytotoxicity assay**

18 CTL assays were performed using previously published methods (Harris et al.,
19 2010; Patton et al., 2004). Briefly, effector cells were derived by stimulating equine
20 PBMC with one of the following for 5 days at 37°C with 5% CO₂: (i) 100ng/ml of α -
21 GalCer, (ii) 6×10^6 *R. equi* ATCC 33701/ml (multiplicity of infection in monocytes
22 approximately 0.3), or (iii) 6×10^6 *R. equi* ATCC 33701/ml plus 100ng/ml of α -GalCer.
23

1 Effectors were then rested for 2 days without antigenic stimulation prior to testing in the
2 CTL assay. Target cells were obtained by eluting adherent peripheral blood adherent
3 cells (PBAC) from MHC class I matched or mismatched horse. The effector cells were
4 then added to target cells previously labeled with ^{51}Cr per ml (PerkinElmer, Waltham,
5 MA). Target cells had been (i) pulsed with 100ng/ml α -GalCer, (ii) infected with 5×10^5
6 live *R. equi*, (iii) infected with 5×10^5 live *R. equi* and pulsed with 1 $\mu\text{g}/\text{ml}$ α -GalCer, or
7 (iv) pulsed with media containing only control vehicle (0.1% DMSO). Specific lysis was
8 calculated using the formula $[(E - S)/(T - S)] \times 100$, where E is the mean of three test
9 wells, S is the mean spontaneous release from three target cell wells without effector
10 cells, and T is the mean total release from three target cell wells with 2% Triton X-100
11 (Sigma-Aldrich). As previously described, significant lysis was defined as 3 standard
12 errors above the negative control value. Cytotoxic assay results shown are a
13 representative example of three animals analyzed in three independent experiments
14 performed in triplicate.

15

16 **2.6 Lymphoproliferation assays**

17 Equine PBMC were plated in 96-well plates at a density of 2.5×10^5 cells/well in
18 100 μl of complete medium. Each well was either (i) pulsed with 100ng/ml α -GalCer, (ii)
19 infected with 2.5×10^5 live *R. equi*/ml, (iii) infected with 2.5×10^5 live *R. equi*/ml and
20 pulsed with 100ng/ml α -GalCer, (iv) pulsed with 10 $\mu\text{g}/\text{ml}$ *R. equi* lipid (v) pulsed with
21 10 $\mu\text{g}/\text{ml}$ *R. equi* lipid and 100ng/ml α -GalCer, (vi) pulsed with 10U/ml human IL-2 as
22 positive control, or (vii) pulsed with media only containing control vehicle (0.1% DMSO).

1 One hour *post R. equi* infection, 20 μ l of complete medium containing 0.05 mg/ml
2 gentamicin sulfate was added to each culture well to kill extracellular bacteria. The
3 plates were then cultured at 37°C with 5% CO₂ for 72h. [³H] thymidine was added at
4 0.5 μ Ci/well 18h prior to the termination of culture. Cells were harvested on an
5 automated 96-well plate harvester (TomTec Inc., Orange, CT) and [³H] Thymidine
6 uptake was measured by liquid scintillation spectroscopy (Wallac Inc., Gaithersburg,
7 MD). Splenocytes from Swiss Webster mouse were isolated as described previously
8 (Sakai et al., 1999), plated into 96-well plates and used as described for equine cells to
9 serve as a positive control. All assays were performed in triplicate. Cells from four
10 animals were analyzed in four independent experiments. In subsequent experiments,
11 the assay was repeated using variants of α -GalCer (100ng/ml) with shorter fatty acyl
12 chains (C8, C12, C16, or C20) and with other previously described or putative NKT cell
13 agonists (See Table 1). The α -GalCer analogue (GalNHAc C20:2), where the hydroxyl
14 group at the 2-position of the galactose head-group was removed, was used as an
15 additional negative control. This hydroxyl group is crucial to the activation of murine and
16 human NKT cells (Jervis et al., 2012). *R. equi* lipid antigens (10 μ g/ml) were used as
17 positive control.

18

19 **2.7 Intradermal testing**

20 To measure in vivo cell-mediated immune responses, a previously described
21 intradermal injection and biopsy method was used with modifications (Liu et al., 2012).
22 Prior to injections, a rectangular area on the neck of three horses was clipped and

1 scrubbed with betadine and alcohol. Intradermal injections consisted of 0.2ml PBS
2 containing the following: (i) 400µg α-GalCer, (ii) 10⁹ heat-killed *R. equi*, (iii) 10⁹ heat-
3 killed *R. equi* with 400µg α-GalCer, or (iv) 400µg *R. equi* lipids. Saline alone containing
4 control vehicle (0.1% DMSO) was also injected as the negative control. After 48h, a
5 2mm skin biopsy from each injection site was collected and stored in RNALater
6 (Ambion, Austin, TX) at 4°C. An additional 4mm skin biopsy sample was placed in 10%
7 formalin for subsequent histopathology.

9 **2.8 Histopathology of skin biopsies**

10 Serial 6µm sections were cut from 4mm skin biopsy samples using a Leica
11 RM2235 Microtome and placed onto poly-L-lysine-coated glass slides for hematoxylin
12 and eosin (H&E) staining. H&E staining was performed according to established
13 protocols (Fischer et al., 2008). All slides were read by a board certified veterinary
14 pathologist (SAH).

16 **2.9 Quantitative Real-Time PCR**

17 The 2mm skin biopsies stored in RNALater were submitted to Dr. David W.
18 Horohov, Laboratory of Equine Immunology, Maxwell H. Gluck Equine Research
19 Center, University of Kentucky (Lexington, KY). Relative quantity (RQ) of gene
20 expression for every sample was assessed by real-time PCR and $2^{-\Delta\Delta CT}$ method,
21 following previously established protocols (Liu et al., 2012). RQ data were natural log

1 transformed to satisfy the assumption of normality. Statistical analyses were performed
2 using SAS software. Results were expressed as log transformed means \pm SEM. Mean
3 differences between treatment groups were evaluated using Fisher's least significant
4 difference (LSD) test. A p value < 0.05 was considered significant.

5

6 **2.10 Flow cytometric analysis – CD1d tetramers**

7 Equine PBMC and murine splenocytes were plated in 75cm² flasks at 4×10^6
8 cells/ml, in 25ml of complete media containing 10U/ml of IL-2 and were stimulated for 0
9 or 5 days with and without 100ng/ml α -GalCer. Before and after stimulation, cells were
10 stained with human or mouse CD1d:Alexa647 tetramers at 1ug/ml, either loaded with α -
11 GalCer or empty (unloaded). The tetramers were generously provided by the National
12 Institutes of Health Tetramer Facility (Atlanta, GA). Briefly, 10^6 equine and murine
13 cells/well were plated in 96-well plates in the respective cocktails containing the
14 species-specific anti-CD3 monoclonal antibodies and CD1d-tetramers diluted in PBS.
15 After 1 hour of incubation, cells were washed and fixed. Data were collected using a
16 FACSort flow cytometer. At least 1×10^6 viable cell events were acquired in the
17 peripheral blood lymphocyte gate using Cell Quest software (Becton Dickinson). Results
18 were analyzed using FCS Express software (De Novo Software, Thornton, Ontario,
19 Canada) and FlowJo software (FlowJo, Ashland, OR). Positive staining was determined
20 by comparing loaded and empty CD1d tetramers.

21

22

1 **3. Results**

2 **3.1 Equine CD1d molecular structure – comparison to other species**

3 Phylogenetic analysis of the eqCD1d binding domain found that eqCD1d was
4 more closely related to huCD1d than any of the other species analyzed (Supplementary
5 Fig. 1), providing evidence of evolutionary proximity and suggesting functional
6 similarities.

7 The high quality eqCD1d molecular model demonstrated that most structural
8 features of previously described CD1d molecules are conserved in horses. However,
9 some characteristics unique to equine CD1d were also apparent. The total volume of
10 the binding cavity of eqCD1d was 1040 Å³. By comparison, the volume of the binding
11 cavities for the reference CD1d molecules were: huCD1d 1009 Å³, boCD1d 985 Å³ and
12 muCD1d 856 Å³ (Fig. 1A-D). The CD1d antigen/ligand binding cavity is composed of
13 two pockets, F' and A'. The F' pocket of CD1d has been described as rather shallow,
14 resulting in a more closed entrance when compared to the other members of the CD1
15 family. This shallowness is due to the formation of an F' roof between the carboxy-
16 terminal end of the α1 helix and the amino-terminal end of the α2 helix. In eqCD1d this
17 groove seems to be slightly larger than in previously described CD1d molecules
18 (Supplementary Fig. 3A). The volume calculated for the equine CD1d F' pocket (489 Å³)
19 is 12% greater than in huCD1d, 9% greater than in boCD1d and 15% greater than in
20 muCD1d. The predicted eqCD1d F' pocket entrance is also wider. This is due to the
21 presence of small hydrophobic residues in place of bulkier side chains, such as the
22 Leu/Ile96Val, Leu/Ile98Val, Phe116Ala, and Phe77Val replacements. Amino acids at
23 positions 96, 98 and 114 have been shown to be critical to structure and function
24 because these residues form the floor of the F' pocket (Supplementary Fig. 3B). As a

1 result of these substitutions, the F' pocket of eqCD1d appears to be deeper than the
2 CD1d F' pocket in other species.

3 In most members of the CD1 family the A' pocket consists of a rounded “donut-
4 like” tunnel that lies under the amino-terminal side of $\alpha 1$ (and hence carboxy-terminal
5 side of $\alpha 2$). The “donut” is formed by a vertical “pole” produced by two conserved
6 residues, Phe70 on the roof of the pocket and Val12 on the floor. In CD1d isoforms,
7 however, the conserved residue Val12 is replaced by Cys12, resulting in a partially
8 transected tunnel. The model predicted that this feature is conserved in eqCD1d
9 (Supplementary Fig. 3C, D). Similar to other species, the modelled A' pocket of eqCD1d
10 forms on the side of the F' pocket, wraps 360° around the A' pole, and connected back
11 to the F' pocket. Bovine CD1d is unique because a Cys166Phe substitution truncates
12 the pocket under $\alpha 2$. This substitution, which limits the size of ligands that the binding
13 cavity can accommodate, is not present in human, murine, or in equine CD1d.

14 Finally, “portals” have been proposed to exist in some CD1 isoforms as a means
15 to accommodate the long lipid tails of ligands whose volume would otherwise exceed
16 that of the cavity. For example, in huCD1b, the so-called C' portal exists at the side of
17 the F' pocket, underneath the $\alpha 2$ link. In huCD1c the D' portal opens up the cavity on
18 the side of the A' pocket. No such portals are predicted in eqCD1d. However, our model
19 of eqCD1d predicts the presence of a novel tunnel/portal at the amino-terminal side $\alpha 1$
20 of the A' pocket. We have putatively named this the “g' tunnel/portal” (Supplementary
21 Fig. 3E). Structurally, the proposed g' portal is an extension of the A' pocket. It appears
22 to result from the replacement of bulky side chains that close the A' pocket in other CD1
23 isomorphs. In eqCD1, a Cys at position 63 together with the His38Tyr substitution leads

1 to formation of the putative tunnel. The tunnel is further formed by a Val (huCD1d)/47Ile
2 substitution at the bottom of the pocket and the conserved Leu66 at the top of the
3 pocket. As a result of its strong interaction with 46Ile, Gln67 seems to have a stabilizing
4 effect comparable with the disulfide bridge that maintains the C' portal in CD1b.
5 Stabilization of the tunnel aperture allows for connection to the exterior face of the
6 binding domain (Supplementary Fig. 3F).

8 **3.2 Binding model: eqCD1d in complex with α -GalCer**

9 A primary goal of our modeling work was to make predictions regarding the ability
10 of eqCD1d to bind and present α -GalCer, and to characterize the predicted interactions.
11 Briefly, the different α -GalCer molecules previously co-crystallized with huCD1d,
12 boCD1d and muCD1d were easily placed in the same orientation when inserted into the
13 eqCD1d model (Fig. 1E-G). There were no steric clashes between the acyl chains and
14 the surface of the modeled cavity, further supporting the hypothesis that equine CD1d
15 should be able to effectively bind α -GalCer.

16 To evaluate the conservation of key residues of eqCD1d that are not part of the
17 binding cavity but are likely to interact with the α -GalCer head-group or the NTK cell
18 receptor, we aligned eqCD1d with huCD1d, boCD1d and muCD1d (Supplementary Fig.
19 4). These amino acids are likely essential for the correct presentation of α -GalCer and
20 recognition of the CD1d/ α -GalCer complex by NKT cells. Among the residues in the
21 CD1d side chains that interact with the sugar head-group of the α -GalCer ligand
22 (huCD1d: Asp80, Asp151, and Trp153 and muCD1d: Asp80, Asp153, and Trp156), all
23 were conserved in eqCD1d (Borg et al., 2007; Koch et al., 2005). Among the 11 CD1d

1 residues known to mediate direct contact of CD1d/ α -GalCer with the NTK T cell
2 receptor, two amino acids (huCD1d: Arg89 Gln150 and muCD1d: Ser89 Asn150) are
3 replaced (with His89 and Asp150) in eqCD1d (Borg et al., 2007).

4

5 **3.3 The effects of α -GalCer on equine CTL**

6 Previous work in our lab demonstrated that the age-associated acquisition of
7 protective immune responses against *R. equi* in horses correlates with the development
8 of *R. equi*-specific CTL. In other species, α -GalCer can act as a potent adjuvant for
9 priming and boosting CTL response. In this study, we first investigated the ability of α -
10 GalCer alone to stimulate equine CTL. As expected, effector cells stimulated with *R.*
11 *equi* produced significant killing of *R. equi*-infected cells but did not kill uninfected cells
12 or cells pulsed with α -GalCer. In contrast, cells stimulated with α -GalCer failed to kill *R.*
13 *equi*-infected or uninfected cells, and they also failed to kill cells pulsed with α -GalCer
14 (Fig. 2A). MHC-class I matched target cells and target cells pulsed with higher and
15 lower concentrations of α -GalCer (1ng/ml to 5 μ g/ml) were also tested and demonstrated
16 similar results (data not shown).

17 To investigate if α -GalCer could enhance the cytotoxic activity of *R. equi*-specific
18 CTL, effector cells were concomitantly stimulated with *R. equi* and α -GalCer and
19 compared with cells stimulated with *R. equi* only. *R. equi*-stimulated cells were able to
20 kill infected targets, and this specific killing increased with an increase in the
21 effector:target cell (E:T) ratio. The effector cells that were concomitantly stimulated with
22 *R. equi* and α -GalCer were also able to kill infected targets, and the specific killing
23 increased with an increase in the E:T ratio. However α -GalCer did not enhance *R. equi*-

1 specific CTL activity. There was no significant α -GalCer-associated increase in the
2 killing of infected cells at any E:T ratio (Fig. 2B). Additional stimulation time points (from
3 24h up to 10 days) and higher and lower concentrations of α -GalCer (1ng/ml to 5 μ g/ml)
4 were also tested and demonstrated similar results (data not shown).

5

6 **3.4 The effects of α -GalCer on proliferation of equine PBMC**

7 In other species, even small amounts of α -GalCer are able to activate the entire
8 NKT cell population. To investigate the capacity of α -GalCer to stimulate lymphocyte
9 proliferation in horses, equine PBMC were pulsed with α -GalCer and cell proliferation
10 measured after 72 hours. Murine cells served as positive controls. After the incubation
11 period, murine cells (which are known to be activated by α -GalCer), demonstrated a
12 significant proliferative response (data not shown, but this response is shown in Fig. 5,
13 Section 3.7 – below). In contrast to murine cells, α -GalCer had no significant effect on
14 equine cells (Fig. 2C). Additional stimulation time points (from 24h to 7 days) and higher
15 and lower concentrations of α -GalCer (1ng/ml to 5 μ g/ml) were also tested and
16 demonstrated similar results (data not shown).

17 To assess the capacity of α -GalCer to act as an immunostimulatory molecule that
18 could enhance the proliferation of equine lymphocyte when co-administrated with *R.*
19 *equi* antigen, equine cells were concomitantly pulsed with α -GalCer and *R. equi* lipid
20 antigens or concomitantly pulsed with α -GalCer and infected with live *R. equi*. These
21 were compared with cells infected with live *R. equi* or stimulated with *R. equi* lipid
22 antigen alone. After 72h of incubation, proliferation was measured and demonstrated

1 that both live *R. equi* and *R. equi* lipids were able to stimulate equine cells; however, α -
2 GalCer did not significantly increase the lymphoproliferative effect when co-
3 administrated with either live *R. equi* or *R. equi* lipid antigens (Fig. 2C).

4

5 **3.5 *In vivo* equine immune responses to α -GalCer**

6 Because of α -GalCer's capacity to trigger a strong immune response in other
7 species, this glycolipid has been tested as an adjuvant for several vaccines. Perhaps
8 our *in vitro* systems are lacking a key component that is nonetheless present *in vivo*. To
9 investigate if α -GalCer would also have an adjuvant/immunostimulatory effect in horses,
10 a group of three animals were randomly selected to test the effects of α -GalCer *in vivo*.
11 As expected, intradermal injection of heat-killed *R. equi* bacteria induced intense
12 dermatitis that was characterized by perivascular lymphocyte accumulations and
13 multifocal accumulation of neutrophils. Injection of *R. equi* lipid antigen induced a similar
14 but less severe inflammatory response. The skin from sites injected with saline
15 (negative control) were within normal limits. Biopsies from skin injected with α -GalCer
16 alone were mostly indistinguishable from the negative control except for some
17 occasional very mild perivascular accumulations of lymphocytes in the deep dermis.
18 The addition of α -GalCer to *R. equi* antigen did not produce detectable increases in the
19 local tissue response (Supplementary Fig. 5).

20 Quantitative real-time PCR performed on mRNA extracted from skin biopsies
21 demonstrated that heat-killed *R. equi* was able to significantly increase the recruitment
22 of CD4, CD8 and CD86 positive cells to the site of injection (Fig. 3). Likewise, there was

1 an increase in mRNA encoding perforin and granzyme. Heat-killed *R. equi* also
2 increased local transcription of the cytokines IFN- γ , IL-12, and IL-4. No increase in the
3 transcript of IL-6 was detected. Although not as potent as heat-killed bacteria, *R. equi*
4 lipid antigens were also able to significantly increase the recruitment of CD4, CD8 and
5 CD86 positive cells to the site of injection and increase the number of transcripts for
6 IFN- γ , granzyme, and perforin. However, there was no significant increase in
7 transcription of IL-12, IL-4 or IL-6. Under the conditions of our experiment, α -GalCer
8 alone was unable to significantly increase the recruitment of any cell marker, nor did it
9 increase the production of any cytokine investigated. Additionally, there was no
10 significant increase in any cell surface marker or cytokine production when α -GalCer
11 was co-injected with heat-killed *R. equi*. Small changes in some cytokines and markers
12 were not statistically significant. A small increase in the production of IL-12 was
13 observed when α -GalCer was co-injected, but was not statistically significant (Fig. 3).

14

15 **3.6 The recognition of equine NKT cells by CD1d-tetramers**

16 The capacity of human CD1d (huCD1d) to present α -GalCer to murine NKT cells
17 and *vice versa* demonstrates the strong conservation of the NKT cell – CD1d interaction
18 between species. Likewise, human and murine CD1d (muCD1d) tetramers loaded with
19 α -GalCer bind NKT cells from both species, whereas empty (unloaded) tetramers bind
20 neither. Investigators have successfully used murine CD1d- α GalCer tetramers as a tool
21 to unequivocally identify an NKT cell population in pigs (Thierry et al., 2012). Therefore,
22 we tested human and muCD1d tetramers binding to equine cells to look for a similar

1 cross-reactive NKT cell population in horses. Briefly, equine PBMC were stained with
2 tetramers and species-specific anti-CD3 monoclonal antibody at the day of cell
3 collection (Day 0). Murine cells were used as positive controls. A second population of
4 PMBC from the same cell collection was studied after being stimulated for 5 days with
5 α -GalCer to expand NKT cells. Gating on viable leukocytes demonstrated that both
6 human and murine α -GalCer loaded-CD1d-tetramers bound a subpopulation of CD3
7 positive murine cells. As previously demonstrated, empty tetramers (no α -GalCer) did
8 not bind. After 5 days of stimulation with α -GalCer, the number of murine cells positive
9 for α -GalCer loaded-tetramers significantly increased, when compared with cells from
10 Day 0 or with unstimulated cells. However, we were unable to detect tetramer-positive
11 cells among the equine CD3 population. Neither α -GalCer-loaded-human CD1d-
12 tetramers nor α -GalCer-loaded-mouse CD1d- tetramers reacted with equine cells.
13 There was no significant staining of equine cells after 5 days of stimulation with α -
14 GalCer, i.e. no tetramer-positive cells were detected among the equine CD3 positive
15 cells after an attempt to expand α -GalCer-reactive cells, as previously demonstrated
16 with murine cells (Fig. 4).

17 **3.7 The effects of α -GalCer analogues and other NKT cell agonists on equine** 18 **PBMC**

19 The bovine CD1d homologue has a shallow antigen-binding pocket compared to
20 other species and consequently cannot accommodate the 26-carbon fatty acyl chain of
21 α -GalCer. Thus full-length α -GalCer does not bind bovine CD1d and does not activate
22 bovine NKT cells (Wang et al., 2012). However, bovine CD1d is able to bind and
23 present shorter α -GalCer analogues that contain a C12 or C16 fatty acyl chain (Nguyen

1 et al., 2013). To explore whether pocket size or conformation might also affect α -GalCer
2 presentation in horses, α -GalCer with shorter acyl chains containing C8, C12, C16 and
3 C20 were produced and their capacity to induce the proliferation of equine lymphocytes
4 was tested. Murine cells, which are known to be activated by α -GalCer, were used as a
5 control – i.e. to confirm that the synthetic lipids were biologically active. After 72h of
6 incubation, all α -GalCer variants were able to stimulate the proliferation of murine
7 lymphocytes. In contrast, none of the short chain analogues induced proliferation of
8 equine cells (Fig 5A).

9 To determine whether other human or murine NKT cell agonists might bind to
10 equine CD1d and activate equine NKT cells, 9 additional lipid compounds were
11 synthesized and tested (Table 1). The specific chemical structures of these lipids are
12 shown in Supplementary Fig. 6. Murine cells demonstrated a significant proliferative
13 response to all nine NKT cell agonists tested (Fig. 5B). Murine cells did not proliferate in
14 response to the negative control that lacked a hydroxyl group at the 2-position of the
15 galactose head group, demonstrating the NKT cell specificity of the assay. As expected,
16 *R. equi* lipids stimulated strong proliferative responses when added to equine PBMC.
17 However, none of the NKT cell agonists were able to induce proliferation of equine cells.

18

1 **4. Discussion**

2 *R. equi* is a soil-borne organism that is ubiquitous in equine environments and an
3 important cause of morbidity and mortality in young horses. Virtually all foals are
4 exposed to *R. equi* shortly after birth. The vast majority of foals develop protective
5 immune responses that operate throughout adult life, whereas affected foals develop
6 pyogranulomatous pneumonia resembling caseous tuberculosis. Attempts to induce or
7 accelerate protective responses in neonatal foals by vaccination have thus far been
8 unsuccessful. We hypothesized that the immunostimulatory glycolipid α -GalCer could
9 be used as an adjuvant to expand equine NKT cells and thereby overcome the relatively
10 poor immune responses that are typical of newborns in virtually all species (Chappuis,
11 1998; Flaminio et al., 2009). Importantly, a successful vaccine to prevent equine
12 rhodococcal pneumonia will likely need to induce type 1 cellular immune responses,
13 including IFN- γ -producing Th1 cells and *R. equi*-specific CTL (Breathnach et al., 2006;
14 Harris et al., 2011; Patton et al., 2005). The CTL have been shown in our laboratory to
15 be MHC-unrestricted and to recognize *R. equi* lipids, likely via the CD1 antigen-
16 presenting system.

17 Using data from other species, we built a detailed model of the equine CD1d
18 molecule. Modeling showed strong homology to previously described CD1d molecules
19 (notably human) and predicted that eqCD1d would bind α -GalCer and present it to NKT
20 cells. Nevertheless, multiple studies, including intradermal injection of α -GalCer *in vivo*
21 and *in vitro* CTL assays, convincingly showed no immunostimulatory effects. Moreover,
22 α -GalCer-loaded CD1d tetramers (which have been shown to be cross-reactive in other

1 species and were used to identify NKT cells in various species) did not bind equine
2 cells, whereas they bound readily to the murine controls.

3 There are several possible explanations for the failure of α -GalCer, α -GalCer
4 short carbon-chain variants, and multiple α -GalCer analogues (all potent NKT cell
5 activators in other species) to stimulate equine cells. One possibility is that none of
6 these molecules is bound by eqCD1d. This explanation seems unlikely considering that
7 the molecular model shows a highly conserved lipid binding groove that should be
8 suitable for loading and presentation of α -GalCer and its variants. Nevertheless, we
9 attempted to test this explanation using biotin-labeled α -GalCer and FACS (data not
10 shown). In our hands, this reagent bound a broad range of equine and non-equine cells
11 non-specifically (binding could not be blocked with unlabeled α -GalCer), raising
12 questions about previous reports where such controls were not in place. Ultimately, we
13 were unable to directly address this unlikely explanation.

14 A more plausible explanation for the lack of an immunostimulatory effect in
15 horses is that the TCR from equine NKT cells are incapable of interacting with eqCD1d
16 and/or recognizing α -GalCer presented by eqCD1d. Although the lipid binding groove of
17 eqCD1d has a very high homology with the huCD1d binding groove, there are
18 substitutions that could affect the interaction of CD1d or α -GalCer-loaded CD1d with
19 equine NKT cells. Among the 11 CD1d residues known to mediate direct contact of
20 CD1d/ α -GalCer with the NTK T cell receptor, two amino acids (huCD1d: Arg89 Gln150
21 and muCD1d: Ser89 Asn150) were replaced (with His89 and Asp150) in eqCD1d (Borg
22 et al., 2007). In humans, the CD1d Arg89 residue forms van der Waals contacts with the
23 NKT-TCR CDR2 β loop and Gln150 forms a hydrogen bond with the Thr98 of the CDR3

1 α loop. A previous study demonstrated that replacement of huCD1d Arg89 with His89,
2 as found in horses, did not significantly affect the activation of human NKT cells (Zhang
3 et al., 2009). The replacement of the CD1d Gln150 with Asp has not been tested, but
4 aspartic acid could potentially conserve the ability to interact with the NKT-TCR loop
5 since this residue is strongly negatively charged and typically behaves like Gln.

6 Other residues towards the surface of the CD1d molecule near the binding
7 groove might also influence the glycolipid head-orientation and the recognition of lipids
8 by NKT cells (Kamada et al., 2001). Among these residues the only replacement found
9 in eqCD1d is Met157 (huCD1d Thr157, muCD1d Thr159). Although this residue does
10 not directly interact with α -GalCer, muCD1d Thr159 forms a conserved extra hydrogen
11 bond with the carbonyl oxygen of galactose-modified α -GalCer analogues (Aspeslagh et
12 al., 2011). Therefore a substitution at this site might affect the orientation of the α -
13 GalCer head and thereby alter presentation.

14 Another possible explanation for the lack of activation of equine cells by α -GalCer
15 is that horses may lack a T cell population homologous to human and murine NKT cells.
16 This explanation seems unlikely considering the strong cross-species conservation of
17 both CD1d and the NKT cell TCR α -chain. However, it is consistent with our failure to
18 find a population of equine PBMC that bound α -GalCer loaded tetramers. An alternative
19 interpretation of this result is that human and murine CD1d- α GalCer tetramers simply do
20 not cross-react with equine NKT cells. Therefore, our current data do not directly
21 address the question of whether horses have NKT cells with similar biological and
22 functional abilities as NKT cells in other species. Likewise, it does not address the
23 potential for expanding this population with an appropriate NKT cell agonist as part of a

1 novel vaccination strategy. A different agonist may be required to broadly active equine
2 NKT cells. Alternatively, it is possible that CD1d-restricted T cells in horses are more
3 antigen-specific (similar to CD1a, CD1b, and CD1c restricted T cells) and that horses
4 lack a broadly reactive iNKT (Type 1 NKT cell) sub-population equivalent to what has
5 been described.

6 In conclusion, further studies are required to confirm the presence of an equine
7 NKT cell and the roles played by lipid antigens in the protection against equine
8 infectious diseases. However, this work suggests that horses are unique among
9 previously described species and provides strong evidence that α -GalCer is unsuitable
10 as an equine vaccine adjuvant in this species.

11

12

1 Acknowledgments

2 We thank Emma Karel and Casey Lawson for their animal handling expertise.
3 Special thanks to Dr. Marc Evans for statistical support. This work was funded by Morris
4 Animal Foundation Grant D10EQ-046 and by United States Department of Agriculture-
5 Agricultural Research Service 5348-32000-034-00D.

6 References

- 7 Aspeslagh, S., Li, Y., Yu, E.D., Pauwels, N., Trappeniers, M., Girardi, E., Decruy, T.,
8 Van Beneden, K., Venken, K., Drennan, M., Leybaert, L., Wang, J., Franck, R.W., Van
9 Calenbergh, S., Zajonc, D.M., Elewaut, D., 2011. Galactose-modified iNKT cell agonists
10 stabilized by an induced fit of CD1d prevent tumour metastasis. *EMBO J* 30, 2294-2305.
11
12 Baker, M.L., Miller, R.D., 2007. Evolution of mammalian CD1: marsupial CD1 is not
13 orthologous to the eutherian isoforms and is a pseudogene in the opossum *Monodelphis*
14 *domestica*. *Immunology* 121, 113-121.
15
16 Bendelac, A., Lantz, O., Quimby, M.E., Yewdell, J.W., Bennink, J.R., Brutkiewicz, R.R., 1995.
17 CD1 recognition by mouse NK1+ T lymphocytes. *Science* 268, 863-865.
18
19 Borg, N., Wun, K., Kjer-Nielsen, L., Wilce, M., Pellicci, D., Koh, R., Besra, G., Bharadwaj, M.,
20 Godfrey, D., McCluskey, J., Rossjohn, J., 2007. CD1d-lipid-antigen recognition by the semi-
21 invariant NKT T-cell receptor. *Nature* 448, 44-49.
22
23 Breathnach, C.C., Sturgill-Wright, T., Stiltner, J.L., Adams, A.A., Lunn, D.P., Horohov, D.W.,
24 2006. Foals are interferon gamma-deficient at birth. *Vet Immunol Immunopathol* 112, 199-209.
25 Brennan, P.J., Brigl, M., Brenner, M.B., 2013. Invariant natural killer T cells: an innate
26 activation scheme linked to diverse effector functions. *Nat Rev Immunol* 13, 101-117.
27
28 Chackerian, A., Alt, J., Perera, V., Behar, S.M., 2002. Activation of NKT cells protects mice
29 from tuberculosis. *Infect Immun* 70, 6302-6309.
30
31 Chang, Y.J., Huang, J.R., Tsai, Y.C., Hung, J.T., Wu, D., Fujio, M., Wong, C.H., Yu, A.L.,
32 2007. Potent immune-modulating and anticancer effects of NKT cell stimulatory glycolipids.
33 *Proc Natl Acad Sci U S A* 104, 10299-10304.
34
35 Chappuis, G., 1998. Neonatal immunity and immunisation in early age: lessons from veterinary
36 medicine. *Vaccine* 16, 1468-1472.
37
38 de Lalla, C., Festuccia, N., Albrecht, I., Chang, H.D., Andolfi, G., Benninghoff, U., Bombelli, F.,
39 Borsellino, G., Aiuti, A., Radbruch, A., Dellabona, P., Casorati, G., 2008. Innate-like effector
40 differentiation of human invariant NKT cells driven by IL-7. *J Immunol* 180, 4415-4424.

- 1
2 Dossa, R.G., Alperin, D.C., Hines, M.T., Hines, S.A., 2014. The equine CD1 gene family is the
3 largest and most diverse yet identified. *Immunogenetics* 66, 33-42.
4
- 5 Fischer, A.H., Jacobson, K.A., Rose, J., Zeller, R., 2008. Hematoxylin and eosin staining of
6 tissue and cell sections. *CSH Protoc* 2008, pdb.prot4986.
7
- 8 Fischer, K., Scotet, E., Niemeyer, M., Koebernick, H., Zerrahn, J., Maillet, S., Hurwitz, R.,
9 Kursar, M., Bonneville, M., Kaufmann, S.H., Schaible, U.E., 2004. Mycobacterial
10 phosphatidylinositol mannoside is a natural antigen for CD1d-restricted T cells. *Proc Natl Acad*
11 *Sci U S A* 101, 10685-10690.
12
- 13 Flaminio, M.J., Nydam, D.V., Marquis, H., Matychak, M.B., Giguère, S., 2009. Foal monocyte-
14 derived dendritic cells become activated upon *Rhodococcus equi* infection. *Clin Vaccine*
15 *Immunol* 16, 176-183.
16
- 17 Fujii, S., Shimizu, K., Smith, C., Bonifaz, L., Steinman, R.M., 2003. Activation of natural killer
18 T cells by alpha-galactosylceramide rapidly induces the full maturation of dendritic cells in vivo
19 and thereby acts as an adjuvant for combined CD4 and CD8 T cell immunity to a coadministered
20 protein. *J Exp Med* 198, 267-279.
21
- 22 Gapin, L., Matsuda, J.L., Surh, C.D., Kronenberg, M., 2001. NKT cells derive from double-
23 positive thymocytes that are positively selected by CD1d. *Nat Immunol* 2, 971-978.
24
- 25 Garzón, D., Bond, P.J., Faraldo-Gómez, J.D., 2009. Predicted structural basis for CD1c
26 presentation of mycobacterial branched polyketides and long lipopeptide antigens. *Mol Immunol*
27 47, 253-260.
28
- 29 Gonzalez-Aseguinolaza, G., Van Kaer, L., Bergmann, C.C., Wilson, J.M., Schmiege, J.,
30 Kronenberg, M., Nakayama, T., Taniguchi, M., Koezuka, Y., Tsuji, M., 2002. Natural killer T
31 cell ligand alpha-galactosylceramide enhances protective immunity induced by malaria vaccines.
32 *J Exp Med* 195, 617-624.
33
- 34 Harris, S., Fujiwara, N., Mealey, R., Alperin, D., Naka, T., Goda, R., Hines, S., 2010.
35 Identification of *Rhodococcus equi* lipids recognized by host cytotoxic T lymphocytes.
36 *Microbiology* 156, 1836-1847.
37
- 38 Harris, S.P., Hines, M.T., Mealey, R.H., Alperin, D.C., Hines, S.A., 2011. Early development of
39 cytotoxic T lymphocytes in neonatal foals following oral inoculation with *Rhodococcus equi*.
40 *Vet Immunol Immunopathol* 141, 312-316.
41
- 42 Huang, Y., Chen, A., Li, X., Chen, Z., Zhang, W., Song, Y., Gurner, D., Gardiner, D., Basu, S.,
43 Ho, D.D., Tsuji, M., 2008. Enhancement of HIV DNA vaccine immunogenicity by the NKT cell
44 ligand, alpha-galactosylceramide. *Vaccine* 26, 1807-1816.
45

- 1 Jervis, P.J., Cox, L.R., Besra, G.S., 2011. Synthesis of a versatile building block for the
2 preparation of 6-N-derivatized α -galactosyl ceramides: rapid access to biologically active
3 glycolipids. *J Org Chem* 76, 320-323.
- 4
- 5 Jervis, P.J., Moulis, M., Jukes, J.P., Ghadbane, H., Cox, L.R., Cerundolo, V., Besra, G.S., 2012.
6 Towards multivalent CD1d ligands: synthesis and biological activity of homodimeric α -
7 galactosyl ceramide analogues. *Carbohydr Res* 356, 152-162.
- 8
- 9 Jervis, P.J., Veerapen, N., Bricard, G., Cox, L.R., Porcelli, S.A., Besra, G.S., 2010. Synthesis and
10 biological activity of alpha-glucosyl C24:0 and C20:2 ceramides. *Bioorg Med Chem Lett* 20,
11 3475-3478.
- 12
- 13 Kamada, N., Iijima, H., Kimura, K., Harada, M., Shimizu, E., Motohashi Si, Kawano, T.,
14 Shinkai, H., Nakayama, T., Sakai, T., Brossay, L., Kronenberg, M., Taniguchi, M., 2001. Crucial
15 amino acid residues of mouse CD1d for glycolipid ligand presentation to V(alpha)14 NKT cells.
16 *Int Immunol* 13, 853-861.
- 17
- 18 Kawano, T., Cui, J., Koezuka, Y., Toura, I., Kaneko, Y., Motoki, K., Ueno, H., Nakagawa, R.,
19 Sato, H., Kondo, E., Koseki, H., Taniguchi, M., 1997. CD1d-restricted and TCR-mediated
20 activation of valpha14 NKT cells by glycosylceramides. *Science* 278, 1626-1629.
- 21
- 22 Kawano, T., Cui, J., Koezuka, Y., Toura, I., Kaneko, Y., Sato, H., Kondo, E., Harada, M.,
23 Koseki, H., Nakayama, T., Tanaka, Y., Taniguchi, M., 1998. Natural killer-like nonspecific
24 tumor cell lysis mediated by specific ligand-activated Valpha14 NKT cells. *Proc Natl Acad Sci*
25 *U S A* 95, 5690-5693.
- 26
- 27 Kinjo, Y., Illarionov, P., Vela, J.L., Pei, B., Girardi, E., Li, X., Li, Y., Imamura, M., Kaneko, Y.,
28 Okawara, A., Miyazaki, Y., Gómez-Velasco, A., Rogers, P., Dahesh, S., Uchiyama, S., Khurana,
29 A., Kawahara, K., Yesilkaya, H., Andrew, P.W., Wong, C.H., Kawakami, K., Nizet, V., Besra,
30 G.S., Tsuji, M., Zajonc, D.M., Kronenberg, M., 2011. Invariant natural killer T cells recognize
31 glycolipids from pathogenic Gram-positive bacteria. *Nat Immunol* 12, 966-974.
- 32
- 33 Kinjo, Y., Tupin, E., Wu, D., Fujio, M., Garcia-Navarro, R., Benhnia, M.R., Zajonc, D.M., Ben-
34 Menachem, G., Ainge, G.D., Painter, G.F., Khurana, A., Hoebe, K., Behar, S.M., Beutler, B.,
35 Wilson, I.A., Tsuji, M., Sellati, T.J., Wong, C.H., Kronenberg, M., 2006. Natural killer T cells
36 recognize diacylglycerol antigens from pathogenic bacteria. *Nat Immunol* 7, 978-986.
- 37
- 38 Kinjo, Y., Wu, D., Kim, G., Xing, G.W., Poles, M.A., Ho, D.D., Tsuji, M., Kawahara, K., Wong,
39 C.H., Kronenberg, M., 2005. Recognition of bacterial glycosphingolipids by natural killer T
40 cells. *Nature* 434, 520-525.
- 41
- 42 Koch, M., Stronge, V.S., Shepherd, D., Gadola, S.D., Mathew, B., Ritter, G., Fersht, A.R., Besra,
43 G.S., Schmidt, R.R., Jones, E.Y., Cerundolo, V., 2005. The crystal structure of human CD1d
44 with and without alpha-galactosylceramide. *Nat Immunol* 6, 819-826.
- 45

- 1 Li, X., Fujio, M., Imamura, M., Wu, D., Vasan, S., Wong, C.H., Ho, D.D., Tsuji, M., 2010.
2 Design of a potent CD1d-binding NKT cell ligand as a vaccine adjuvant. *Proc Natl Acad Sci U S*
3 *A* 107, 13010-13015.
- 4
- 5 Liu, C., Cook, F.R., Cook, S.J., Craigo, J.K., Even, D.L., Issel, C.J., Montelaro, R.C., Horohov,
6 D.W., 2012. The determination of in vivo envelope-specific cell-mediated immune responses in
7 equine infectious anemia virus-infected ponies. *Vet Immunol Immunopathol* 148, 302-310.
- 8
- 9 Liu, Y., Goff, R.D., Zhou, D., Mattner, J., Sullivan, B.A., Khurana, A., Cantu, C., Ravkov, E.V.,
10 Ibegbu, C.C., Altman, J.D., Teyton, L., Bendelac, A., Savage, P.B., 2006. A modified alpha-
11 galactosyl ceramide for staining and stimulating natural killer T cells. *J Immunol Methods* 312,
12 34-39.
- 13
- 14 Looringh van Beeck, F.A., Reinink, P., Hermsen, R., Zajonc, D.M., Laven, M.J., Fun, A.,
15 Troskie, M., Schoemaker, N.J., Morar, D., Lenstra, J.A., Vervelde, L., Rutten, V.P., van Eden,
16 W., Van Rhijn, I., 2009. Functional CD1d and/or NKT cell invariant chain transcript in horse,
17 pig, African elephant and guinea pig, but not in ruminants. *Mol Immunol* 46, 1424-1431.
- 18
- 19 Lopez, A.M., Hines, M.T., Palmer, G.H., Knowles, D.P., Alperin, D.C., Hines, S.A., 2003.
20 Analysis of anamnestic immune responses in adult horses and priming in neonates induced by a
21 DNA vaccine expressing the vapA gene of *Rhodococcus equi*. *Vaccine* 21, 3815-3825.
- 22
- 23 Lopez, A.M., Townsend, H.G., Allen, A.L., Hondalus, M.K., 2008. Safety and immunogenicity
24 of a live-attenuated auxotrophic candidate vaccine against the intracellular pathogen
25 *Rhodococcus equi*. *Vaccine* 26, 998-1009.
- 26
- 27 Makino, Y., Kanno, R., Ito, T., Higashino, K., Taniguchi, M., 1995. Predominant expression of
28 invariant V alpha 14+ TCR alpha chain in NK1.1+ T cell populations. *Int Immunol* 7, 1157-
29 1161.
- 30
- 31 Mealey, R.H., Stone, D.M., Hines, M.T., Alperin, D.C., Littke, M.H., Leib, S.R., Leach, S.E.,
32 Hines, S.A., 2007. Experimental *Rhodococcus equi* and equine infectious anemia virus DNA
33 vaccination in adult and neonatal horses: effect of IL-12, dose, and route. *Vaccine* 25, 7582-
34 7597.
- 35
- 36 Metelitsa, L.S., Naidenko, O.V., Kant, A., Wu, H.W., Loza, M.J., Perussia, B., Kronenberg, M.,
37 Seeger, R.C., 2001. Human NKT cells mediate antitumor cytotoxicity directly by recognizing
38 target cell CD1d with bound ligand or indirectly by producing IL-2 to activate NK cells. *J*
39 *Immunol* 167, 3114-3122.
- 40
- 41 Miyamoto, K., Miyake, S., Yamamura, T., 2001. A synthetic glycolipid prevents autoimmune
42 encephalomyelitis by inducing TH2 bias of natural killer T cells. *Nature* 413, 531-534.
- 43
- 44 Monzon-Casanova, E., Steiniger, B., Schweigle, S., Clemen, H., Zdziebło, D., Starick, L.,
45 Müller, I., Wang, C.R., Rhost, S., Cardell, S., Pyz, E., Herrmann, T., 2010. CD1d expression in

- 1 paneth cells and rat exocrine pancreas revealed by novel monoclonal antibodies which
2 differentially affect NKT cell activation. PLoS One 5.
3
- 4 Moody, D.B., Zajonc, D.M., Wilson, I.A., 2005. Anatomy of CD1-lipid antigen complexes. Nat
5 Rev Immunol 5, 387-399.
6
- 7 Nguyen, T.K., Koets, A.P., Vordermeier, M., Jervis, P.J., Cox, L.R., Graham, S.P., Santema,
8 W.J., Moody, D.B., van Calenbergh, S., Zajonc, D.M., Besra, G.S., Van Rhijn, I., 2013. The
9 bovine CD1D gene has an unusual gene structure and is expressed but cannot present α -
10 galactosylceramide with a C26 fatty acid. Int Immunol 25, 91-98.
11
- 12 Nishimura, T., Kitamura, H., Iwakabe, K., Yahata, T., Ohta, A., Sato, M., Takeda, K., Okumura,
13 K., Van Kaer, L., Kawano, T., Taniguchi, M., Nakui, M., Sekimoto, M., Koda, T., 2000. The
14 interface between innate and acquired immunity: glycolipid antigen presentation by CD1d-
15 expressing dendritic cells to NKT cells induces the differentiation of antigen-specific cytotoxic T
16 lymphocytes. Int Immunol 12, 987-994.
17
- 18 Patton, K., McGuire, T.C., Fraser, D.G., Hines, S.A., 2004. *Rhodococcus equi*-infected
19 macrophages are recognized and killed by CD8⁺ T lymphocytes in a MHC class I- unrestricted
20 fashion. Infect Immun 72, 7073-7083.
21
- 22 Patton, K.M., McGuire, T.C., Hines, M.T., Mealey, R.H., Hines, S.A., 2005. *Rhodococcus equi*-
23 specific cytotoxic T lymphocytes in immune horses and development in asymptomatic foals.
24 Infect Immun 73, 2083-2093.
25
- 26 Rahman, M., Herron, L., Kapur, V., Meijer, W., Byrne, B., Ren, J., Nicholson, V., Prescott, J.,
27 2003. Partial genome sequencing of *Rhodococcus equi* ATCC 33701. Vet Microbiol 94, 143-
28 158.
29
- 30 Reilly, E.C., Thompson, E.A., Aspeslagh, S., Wands, J.R., Elewaut, D., Brossay, L., 2012.
31 Activated iNKT cells promote memory CD8⁺ T cell differentiation during viral infection. PLoS
32 One 7, e37991.
33
- 34 Sada-Ovalle, I., Sköld, M., Tian, T., Besra, G.S., Behar, S.M., 2010. Alpha-galactosylceramide
35 as a therapeutic agent for pulmonary *Mycobacterium tuberculosis* infection. Am J Respir Crit
36 Care Med 182, 841-847.
37
- 38 Sakai, T., Naidenko, O.V., Iijima, H., Kronenberg, M., Koezuka, Y., 1999. Syntheses of
39 biotinylated alpha-galactosylceramides and their effects on the immune system and CD1
40 molecules. J Med Chem 42, 1836-1841.
41
- 42 Silk, J.D., Salio, M., Reddy, B.G., Shepherd, D., Gileadi, U., Brown, J., Masri, S.H., Polzella, P.,
43 Ritter, G., Besra, G.S., Jones, E.Y., Schmidt, R.R., Cerundolo, V., 2008. Cutting edge:
44 nonglycosidic CD1d lipid ligands activate human and murine invariant NKT cells. J Immunol
45 180, 6452-6456.
46

- 1 Spada, F.M., Koezuka, Y., Porcelli, S.A., 1998. CD1d-restricted recognition of synthetic
2 glycolipid antigens by human natural killer T cells. *J Exp Med* 188, 1529-1534.
3
- 4 Subrahmanyam, P., Webb, T.J., 2012. Boosting the Immune Response: The Use of iNKT cell
5 ligands as vaccine adjuvants. *Front Biol (Beijing)* 7, 436-444.
6
- 7 Thierry, A., Robin, A., Giraud, S., Minouflet, S., Barra, A., Bridoux, F., Hauet, T., Touchard, G.,
8 Herbelin, A., Gombert, J.M., 2012. Identification of invariant natural killer T cells in porcine
9 peripheral blood. *Vet Immunol Immunopathol* 149, 272-279.
10
- 11 Venkataswamy, M., Baena, A., Goldberg, M., Bricard, G., Im, J., Chan, J., Reddington, F.,
12 Besra, G., Jacobs, W.J., Porcelli, S., 2009. Incorporation of NKT cell-activating glycolipids
13 enhances immunogenicity and vaccine efficacy of *Mycobacterium bovis* bacillus Calmette-
14 Guerin. *J Immunol* 183, 1644-1656.
15
- 16 Vázquez-Boland, J.A., Giguère, S., Hapeshi, A., MacArthur, I., Anastasi, E., Valero-Rello, A.,
17 2013. *Rhodococcus equi*: the many facets of a pathogenic actinomycete. *Vet Microbiol* 167, 9-
18 33.
19
- 20 Wang, J., Guillaume, J., Pauwels, N., Van Calenbergh, S., Van Rhijn, I., Zajonc, D.M., 2012.
21 Crystal structures of bovine CD1d reveal altered α GalCer presentation and a restricted A' pocket
22 unable to bind long-chain glycolipids. *PLoS One* 7, e47989.
23
- 24 Yu, K.O., Im, J.S., Molano, A., Dutronc, Y., Illarionov, P.A., Forestier, C., Fujiwara, N., Arias,
25 I., Miyake, S., Yamamura, T., Chang, Y.T., Besra, G.S., Porcelli, S.A., 2005. Modulation of
26 CD1d-restricted NKT cell responses by using N-acyl variants of alpha-galactosylceramides. *Proc*
27 *Natl Acad Sci U S A* 102, 3383-3388.
28
- 29 Zhang, P., Li, D., Stewart-Jones, G., Shao, X., Zhang, Y., Chen, Q., Li, Y., He, Y.W., Xu, X.N.,
30 Zhang, H.T., 2009. A single amino acid defines cross-species reactivity of tree shrew (*Tupaia*
31 *belangeri*) CD1d to human invariant natural killer T (iNKT) cells. *Immunology* 128, 500-510.
32
- 33 Zhang, W., Lonning, S.M., McGuire, T.C., 1998. Gag protein epitopes recognized by ELA-A-
34 restricted cytotoxic T lymphocytes from horses with long-term equine infectious anemia virus
35 infection. *J Virol* 72, 9612-9620.
36

1 **Fig. 1. Structural comparison of the binding domains of CD1d across species. (A-**
 2 **D)** In each image, the protein fold is shown in transparent grey cartoon format, whilst
 3 the binding groove is shown as a green wireframe structure. Each CD1d molecule is
 4 viewed on the lateral $\alpha 1$ side. (A) eqCD1d, (B) huCD1d, (C) boCD1d, and (D) muCD1d.
 5 **(E-G)** Snapshots showing the eqCD1d cavity bound to (E) huCD1d α -GalCer
 6 (C18;C26), (F) boCD1d α -GalCer (C18;C16) and (G) muCD1d OCH (α -GalCer
 7 analogue) (C9;C26). The α -GalCer (CPK wireframe format) are shown bound within the
 8 cavity (white wireframe surface). Each binding domain is viewed from the $\alpha 1$ side.
 9 These models predict that the eqC1d binding groove will accommodate all three α -
 10 GalCer molecules.

11
 12 **Fig. 2. Effects of α -GalCer on equine immune cells. (A, B) CTL Assays: (A)** Effector
 13 cells from equine PBMCs were stimulated for 7 days with α -GalCer (grey bars) or *R.*
 14 *equi* (horizontally striped bars). Effector cells were then added to MHC mismatched
 15 target cells at a 9:1 E:T cell ratio. Target cells were either pulsed with α -GalCer
 16 (100ng/ml), infected with *R. equi*, or untreated (negative control). **(B)** Effector cells
 17 stimulated for 7 days with either *R. equi* (horizontally striped bars), *R. equi* + α -GalCer
 18 @ 100ng/ml (vertically striped bars), or media containing control vehicle (no stimulation
 19 - open bars) were added to *R. equi*-infected target cells at E:T ratios of 1:1, 3:1 or 9:1.
 20 In all CTL experiments, the percentage specific lysis was measured using a chromium
 21 release assay. Data shown is a representative of 3 independent experiments performed
 22 in 3 horses. An asterisk indicates significant lysis, defined as 3 standard errors above
 23 the negative control value. **(C) Lymphoproliferation:** Equine cells were pulsed with

1 media only (no stimulation - open bars), α -GalCer (grey bars), live *R. equi* (horizontally
2 striped bars), *R. equi* lipids (ascendant striped bars) or IL-2 (black bars - positive
3 control). Cells were also concomitantly pulsed with live *R. equi* plus α -GalCer (vertically
4 striped bars) or *R. equi* lipids plus α -GalCer (descendent striped bars). The proliferation
5 of equine cells using H^3 -Thymidine uptake was assessed after 72 hours of stimulation.
6 Data shown (Horse #181, Horse #189, and Horse #187) are from 3 independent
7 experiments; each value is the mean of triplicates plus standard deviation. An asterisk
8 represents significant difference when compared with media control (p value < 0.05).

9
10 **Fig. 3. *In vivo* effects of α -GalCer in horses: Recruitment of immune cells and**
11 **transcription of cytokines and cytolytic molecules as measured by quantitative**
12 **RT-PCR.** Adult horses were injected intradermally with saline only (open bars), α -
13 GalCer alone (grey bars), heat-killed *R. equi* (horizontally striped bars), heat-killed *R.*
14 *equi* plus α -GalCer (vertically striped bars) or *R. equi* lipids (ascendant striped bars).
15 mRNA expression for **(A)** cell markers and **(B)** cytokines and cytolytic molecules were
16 detected by Real-Time PCR in biopsy samples from the injection site. Relative
17 increase/decrease was compared to injection with saline only and results were natural
18 log transformed to satisfy the statistic assumption. Data are from 3 animals are
19 expressed as means plus standard error. An asterisk represents significant difference
20 when compared with saline control (p value < 0.05).

21
22 **Fig. 4. Failure of CD1d-tetramers to bind an equine NKT population.** Equine PBMC
23 and murine cells were membrane-labeled with anti-CD3-Alexa488 species-specific

1 monoclonal antibodies (x-axis), and stained with human or murine CD1d tetramers-
 2 Alexa647 (y-axis) that were either loaded with α -GalCer or empty, before (day 0) or after
 3 (day 5) stimulation with α -GalCer (100ng/ml) + IL-2. Number in gates indicates
 4 percentage of live cells that were concomitantly positive for CD3 and the tetramers. *One*
 5 representative case showing 1×10^6 viable cells events is shown. An asterisk indicates
 6 a significant difference when compared with the respective matching empty tetramers.

7
 8 **Fig. 5. Effects of α -GalCer analogues and other NKT cell agonists on equine**
 9 **PBMC. (A)** Equine PBMC and murine cells, as a positive control, were pulsed with
 10 media alone (open bars), α -GalCer (100ng/ml) containing alkyl chains ranging between
 11 eight carbons to 26 carbons (grey bars) or with IL-2 (black bars – positive control). **(B)**
 12 Equine PBMC and murine cells, were pulsed with media alone (open bars), α -GalCer
 13 (grey bar), the additional nine NKT cell agonists (100ng/ml), lipid control, *R. equi* lipids
 14 (ascendant striped bars) or IL-2 (black bars - positive control). The proliferation of cells
 15 using thymidine uptake was assessed after 72 hours of stimulation. Data shown (Horse
 16 #184, #185 and #188) are representative of 4 independent experiments performed in 4
 17 horses, and each value shows the mean of triplicates plus standard deviation. An
 18 asterisk represents significant difference when compared with media control (p value
 19 < 0.05).

20
 21 **Table 1** NKT cell agonists tested

Glycolipids	Reference
OCH	(Miyamoto et al., 2001)
α -GalCer C20:2	(Yu et al., 2005)
7DW8-5	(Li et al., 2010)

α -GalCer C4Ph	(Chang et al., 2007)
α -GlcCer C26	(Kinjo et al., 2006)
α -GalDAG	(Jervis et al., 2010)
α -ThrCer	(Silk et al., 2008)
PBS-57	(Liu et al., 2006)
Dimer	(Jervis et al., 2012)
GalNHAc C20:2	PJJ

1

2

Accepted Manuscript

Accepted Manuscript